Clinical Trials Logo

Sarcoidosis clinical trials

View clinical trials related to Sarcoidosis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06409585 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

CHIEFTain
Start date: May 1, 2023
Phase:
Study type: Observational

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot of these conditions are still not fully understood and treatment options are limited. We here aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of heart muscle scarring. This radioactive dye is being used in humans particularly in identifying and monitoring cancers and has shown promise in identifying scarring in the heart as well. This will help us not only understand the underlying disease process and risk stratify these patients but also potentially help us develop new targeted therapies that can affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in the process.

NCT ID: NCT06347939 Recruiting - Lung Cancer Clinical Trials

Mediastinal EBUS Cryobiopsy Study In Sweden

MECRIS
Start date: April 1, 2024
Phase:
Study type: Observational

This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other. The investigators conduct EBUS TBNA and EBUS TBMCB on all the study participants.The cryobiopsy samples are numbered to evaluate the number of biopsies needed to reach a definite diagnosis and to assess the added value of every sample taken from the same participitant. Every participitant's own samples are compared to each other and added value of EBUS TBMCB is defined as the difference in diagnostic yield between the EBUS TBNA alone and the combination of EBUS TBNA with EBUS TBMCB. Diagnostic yield is defined as the efficacy of the investigation module in reaching a definite diagnosis (percentage of cases with a definite diagnosis). Follow up four weeks after the procedure to assess the risk for postoperative complications.

NCT ID: NCT06238037 Recruiting - Sarcoidosis Clinical Trials

Bone Mineral Density in Patients With Sarcoidosis

Start date: December 1, 2019
Phase:
Study type: Observational

To assess the frequency and risk factors of decreased bone mineral density (BMD) and vertebral fractures in Danish patients with sarcoidosis.

NCT ID: NCT06234384 Recruiting - Sarcoidosis Clinical Trials

Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)

Start date: July 2013
Phase:
Study type: Observational [Patient Registry]

The goal of the study is to create a longitudinal study of patient reported outcomes for people living with sarcoidosis that maintains privacy. Patients report on the following: demographics, disease symptoms, diagnostic journey, provider experience, disease treatment, and burden of disease. The goal is to create a natural history of sarcoidosis, support research, and better understand the needs of the sarcoidosis community.

NCT ID: NCT06220526 Recruiting - Clinical trials for Suspected Sarcoidosis

Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis

Start date: August 18, 2023
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial aims to examine whether sample collection with Franseen-type needles are effective for the diagnosis of sarcoidosis, as defined by improved sample quality for pathological diagnosis compared to the conventional Menghini-type needle.

NCT ID: NCT06205121 Recruiting - Clinical trials for Pulmonary Sarcoidosis

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

Start date: March 21, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

NCT ID: NCT06131112 Recruiting - Cardiac Sarcoidosis Clinical Trials

Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis

CuDOSIS
Start date: November 1, 2023
Phase:
Study type: Observational

The purpose of the CuDOSIS study is to examine the diagnostic value of activated macrophage imaging in patients with or under evaluation for cardiac sarcoidosis. The PET/CT tracer 64Cu-DOTATATE is used as a tool to identify activated macrophages. The trial is an open-label prospective study. The study will include 54 participants from the Department of Cardiology and the Department of Clinical Physiology, Nuclear Medicine, and PET at Rigshospitalet. Further, the study will include data from 22 patients with NET who have been scanned with 64Cu-DOTATATE PET/CT previously as negative controls. Participants will be included in the following groups: Group A: 22 patients with clinically suspected cardiac sarcoidosis Group B: 22 patients with known cardiac sarcoidosis Group C: Up to 10 patients with clinically suspected or confirmed acute lymphocytic myocarditis Group D: 22 patients with NET without known inflammatory heart disease who have previously been scanned with 64Cu-DOTATATE PET/CT as part of their routine diagnostic work-up or follow-up (control group)

NCT ID: NCT06113991 Recruiting - Clinical trials for Pulmonary Sarcoidosis

Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis

BERYSARC
Start date: June 14, 2023
Phase:
Study type: Observational

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood. The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

NCT ID: NCT05916638 Recruiting - Tuberculosis Clinical Trials

MoMa Signature During Granulomatosis

MOSAR
Start date: January 15, 2024
Phase:
Study type: Observational

Sarcoidosis is a systemic inflammatory disease characterized by unspecific granuloma formation. Our hypothesis is that granuloma formation and maintenance mainly relies on the overactivation of monocytes (Mo) and macrophages (Ma). To this end, the study aims (i) to define MoMa systemic signature in sarcoidosis, (ii) to characterize this signature in situ on tissue samples, and (iii) to identify causative factors that participate to the MoMa chronic overactivation. Thus, a cohort of sarcoidosis patients will be compared with tuberculosis patients. The MoMa systemic signature will be defined on whole blood (TruCulture model) and then in situ through different methods (multi-parameter spectral flow cytometry, RNA-seq, Luminex, imaging mass cytometry). The epigenome of monocytes will be studied thanks to CUT&Tag. The MoMa systemic signature will be defined ex vivo at different time points during the course of the disease with phenotypic, transcriptomic, cytokine and functional approaches. The previously identified signature will be studied in situ and completed by the characterization of granuloma architecture and microenvironmental interactions, which could be modulated by epigenetic modifications. Hence, the epigenome of monocytes will be analyzed in two groups (sarcoidosis and tuberculosis). These results would allow to better understand sarcoidosis physiopathology and, in fine, may raise new therapeutic strategies. Finally, the study could challenge the dogma on innate immunity/auto-inflammation versus adaptive immunity/auto-immunity/memory.

NCT ID: NCT05890729 Recruiting - Clinical trials for Pulmonary Sarcoidosis

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

Start date: November 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis